Sign inSubscribe

target directory

anemia in hemodialysis dependent chronic kidney disease patients clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT02075463
Source recordAI-normalized

A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO

The clinical trial evaluated GSK1278863 for treating anemia in patients with chronic kidney disease who are hyporesponsive to rhEPO. The study aimed to assess the drug's safety and efficacy over a 16-week treatment period, following a 4-week run-in with rhEPO. The trial was sponsored by GlaxoSmithKline and included 15 participants, with a focus on optimizing hemoglobin levels.

AI analysis

Indication: Anemia

Modality: small molecule

Target: Anemia in hemodialysis-dependent chronic kidney disease patients

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Jun 21, 2017

Ingested: May 31, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in hemodialysis-dependent chronic kidney disease patients

View original source fields

Condition raw: Anemia

Condition normalized: Anemia

Modality raw: Anemia

Modality normalized: small molecule

Target raw: Anemia in hemodialysis-dependent chronic kidney disease patients

Target normalized: Anemia in hemodialysis-dependent chronic kidney disease patients

Open report